<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863365</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-201-S301</org_study_id>
    <nct_id>NCT04863365</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PHP-201 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pH Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pH Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and&#xD;
      safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a selective ROCK inhibitor, PHP-201 is designed to alleviate the side effects, which are&#xD;
      the disadvantages of existing intraocular pressure reducing agents, while exhibiting&#xD;
      sufficient intraocular pressure-lowering effect in glaucoma patients. This clinical trial&#xD;
      aims to provide a new therapeutic option by evaluating the efficacy and safety of PHP-201&#xD;
      0.5% in patients with primary open-angle glaucoma or ocular hypertension who require&#xD;
      intraocular pressure reduction therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean IOP change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diurnal intraocular pressure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean of diurnal IOP change from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse event</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Safety assessed by number of participants experienced treatment-emergent adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A matching placebo ophthalmic solution, TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHP-201 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHP-201 0.5% ophthalmic solution, TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ophthalmic solution</intervention_name>
    <description>A matching placebo ophthalmic solution, 3 drops daily, 28 days</description>
    <arm_group_label>Placebo treatment</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHP-201 ophthalmic solution</intervention_name>
    <description>PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days</description>
    <arm_group_label>PHP-201 treatment</arm_group_label>
    <other_name>Sovesudil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:&#xD;
&#xD;
          1. The age of 19 years or older&#xD;
&#xD;
          2. Diagnosis of open-angle glaucoma (POAG) or ocular hypertension (OH)&#xD;
&#xD;
          3. Intraocular Pressure(IOP) ≤ 35mmHg at both eye and IOP ≥ 22mmHg at either eye&#xD;
&#xD;
          4. Shaffer's grading &gt; 2&#xD;
&#xD;
          5. Best-corrected visual acuity in both eye equivalent to 0.2logMar&#xD;
&#xD;
          6. Able and willing to give signed informed consent&#xD;
&#xD;
        Subject Exclusion Criteria:&#xD;
&#xD;
          1. Central corneal thickness &lt;500㎛ or &gt;600㎛&#xD;
&#xD;
          2. Medical history of following&#xD;
&#xD;
               -  Closed-angle glaucoma, pigment dispersion syndrome, pseudoexfoliation,&#xD;
                  narrow-angle glaucoma&#xD;
&#xD;
               -  Advanced glaucomatous loss; mean deviation (MD) &lt; -12dB&#xD;
&#xD;
               -  Moderate to severe inflammatory/infectious disease in either eye&#xD;
&#xD;
               -  Advanced retinopathy&#xD;
&#xD;
               -  Surgical or laser therapy for glaucoma treatment&#xD;
&#xD;
          3. Have confirmed the following at the screening visit&#xD;
&#xD;
               -  SBP ≥ 180mmHg or DBP ≥ 110mmHg&#xD;
&#xD;
               -  HbA1c &gt; 9.0%&#xD;
&#xD;
               -  CrCl &lt; 30mL/min&#xD;
&#xD;
               -  AST or ALT ≥ 3 X ULN&#xD;
&#xD;
               -  Unstable angina, myocardial infarction, transient ischemic attack, cerebral&#xD;
                  stroke, coronary artery bypass graft, or coronary angioplasty within 24 weeks&#xD;
&#xD;
               -  History of malignant tumor with 5 years&#xD;
&#xD;
               -  History of the causative disease that may cause secondary glaucoma, including a&#xD;
                  history of steroid administration for more than 4 weeks&#xD;
&#xD;
          4. Conditions need to wear contact lenses during the study&#xD;
&#xD;
          5. Known hypersensitivity to any component of the investigational product&#xD;
&#xD;
          6. Who has administered topical/systemic drugs that may affect the study within a certain&#xD;
             period prior to eligibility check or are expected to need administration during the&#xD;
             study duration&#xD;
&#xD;
               -  Prostaglandin analogues: 5 weeks&#xD;
&#xD;
               -  β-blockers: 4 weeks&#xD;
&#xD;
               -  ROCK inhibitors: 4 weeks&#xD;
&#xD;
               -  α/β-adrenergic agonists: 2 weeks&#xD;
&#xD;
               -  Muscarinic agonists: 1 week&#xD;
&#xD;
               -  Carbonic anhydrase inhibitors: 1 week&#xD;
&#xD;
               -  Systemic corticosteroids: 4 weeks&#xD;
&#xD;
          7. Pregnant or breast-feeding&#xD;
&#xD;
          8. Who disagreed with the use of the methods of proper contraception during the study&#xD;
             duration&#xD;
&#xD;
          9. Administration or use of other investigational drugs/devices prior to the screening&#xD;
             visit within its 5 half-lives or 30 days, whichever is longer&#xD;
&#xD;
         10. Unsuitable for participation in the study according to the judgment of the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Younyoung Hwang</last_name>
    <role>Study Director</role>
    <affiliation>pH Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Younyoung Hwang</last_name>
    <phone>+82 31 779 5301</phone>
    <email>younyoung.hwang@ph-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hopsital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>KiHo Park, MD. PhD</last_name>
    </contact>
    <investigator>
      <last_name>KiHo Park, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Primary Open-angle Glaucoma</keyword>
  <keyword>ROCK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

